       Document 0782
 DOCN  M9620782
 TI    HIV-1 recombinant poxvirus vaccine induces cross-protection against
       HIV-2 challenge in rhesus macaques [see comments]
 DT    9602
 AU    Abimiku AG; Franchini G; Tartaglia J; Aldrich K; Myagkikh M; Markham PD;
       Chong P; Klein M; Kieny MP; Paoletti E; et al; Laboratory of Tumor Cell
       Biology, National Cancer Institute,; National Institutes of Health,
       Bethesda, Maryland 20892-4255,; USA.
 SO    Nat Med. 1995 Apr;1(4):321-9. Unique Identifier : AIDSLINE MED/96071441
 CM    Comment in: Nat Med 1995 Apr;1(4):295-7
 AB    Rhesus macaques were immunized with attenuated vaccinia or canarypox
       human immunodeficiency virus type 1 (HIV-1) recombinants and boosted
       with HIV-1 protein subunits formulated in alum. Following challenge with
       HIV-2SBL6669, three out of eight immunized macaques resisted infection
       for six months and another exhibited significantly delayed infection,
       whereas all three naive controls became infected. Immunizations elicited
       both humoral and cellular immune responses; however, no clear correlates
       of protection were discerned. Although more extensive studies are now
       called for, this first demonstration of cross-protection between HIV-1
       and -2 suggests that viral variability may not be an insurmountable
       problem in the design of a global AIDS vaccine.
 DE    Amino Acid Sequence  Animal  Avipoxvirus  *AIDS Vaccines/ADMINISTRATION
       & DOSAGE/IMMUNOLOGY  Enzyme-Linked Immunosorbent Assay  Gene Products,
       env/CHEMISTRY/IMMUNOLOGY  HIV Antibodies/ANALYSIS  HIV Core Protein
       p24/IMMUNOLOGY  HIV Envelope Protein gp120/CHEMISTRY/IMMUNOLOGY  HIV
       Infections/IMMUNOLOGY/*PREVENTION & CONTROL  HIV-1/*IMMUNOLOGY
       HIV-2/*IMMUNOLOGY  Immunization, Secondary  Macaca mulatta  Molecular
       Sequence Data  Peptide Fragments  Pilot Projects  Protein
       Precursors/CHEMISTRY/IMMUNOLOGY  Vaccination  *Vaccines,
       Synthetic/ADMINISTRATION & DOSAGE/IMMUNOLOGY  Vaccinia Virus  JOURNAL
       ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).

